vendredi 3 janvier 2020

Onco Actu du 3 janvier 2020


3.1.1 PRÉVENTION - TABAC - E-CIGS



Vape Shops Saved for Now: Dodged One Bullet, But Now Must Dodge Another One [The Rest of The Story]











With Partial Flavor Ban, Trump Splits the Difference on Vaping [NY Times]










Trump administration restricts some e-cigarette flavors [Reuters]











Vaping industry offers academic scholarships to high school kids [Reuters]











FDA finalizes enforcement policy on unauthorized flavored cartridge-based e-cigarettes that appeal to children, including fruit and mint [FDA]











3.3 PRÉVENTION - VACCINS



This Italian scientist has become a celebrity by fighting vaccine skeptics [Science]










4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS



Illumina & PacBio Throw In The Towel [Omics! Omics!]










Illumina, Pacific Biosciences Abandon $1.2B Acquisition Deal [Genome Web]











After Antitrust Challenges, Illumina and PacBio Throw in Towel on Merger [Xconomy]











Illumina and Pacific Biosciences Announce Termination of Merger Agreement [BusinessWire]











4.5 DÉP., DIAG. & PRONO. - COLORECTAL



Circulating Tumor DNA Methylation Profiles May Aid in Colorectal Cancer Early Diagnosis, Prognosis [Genome Web]











Machine learning accurate at colorectal cancer diagnosis, may also predict survival [UPI]











4.9 DÉP., DIAG. & PRONO. - SEIN



AI shows promise for breast cancer screening [Nature]










Artificial intelligence could help breast screening save more lives [Cancer Research UK]











5.1 TRAITEMENTS - PRÉ-CLINIQUE



How a transporter protein could be a new target for colorectal cancer [Fierce Biotech]











5.10 TRAITEMENTS - ESSAIS



Half the amount of chemo prevents testicular cancer from coming back, new trial shows [Institute of Cancer Research]











5.12.6 IMMUNOTHÉRAPIES - AMM



Milestone for Biopharmaceuticals in China [Boehringer Ingelheim]











BeiGene scores first China OK with PD-1 — to be manufactured by Boehringer Ingelheim [EndPoints]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Despite secret discount, Roche's Tecentriq hits NICE roadblock in small-cell lung cancer [Fierce Pharma]











Tough times for Tecentriq as NICE once again slaps down Roche's immunotherapy — slight benefit not worth price [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Additional evidence needed to assess histology-independent cancer drugs says paper co-authored by NICE staff [Nice]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv for Metastatic Urothelial Cancer [ESMO]











5.4 TRAITEMENTS - ECONOMIE



Pfizer, BMS, Gilead, AbbVie and others hike prices on hundreds of meds to ring in 2020 [Fierce Pharma]











New year, new (higher) drug prices [EndPoints]











6.10 POLITIQUES



U.K. looks to shake up trial, medicines regulation amid Brexit [Fierce Biotech]